IL4 and uterine cervix carcinoma in situ: Releasereached a maximum for IL-10 and IL-4 in patients with CIN III and decreasedsignificantly for both cytokines in patients with invasive carcinoma.(K. W. test: P=.019 for IL-10 and P=.033 for IL-4).